Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Cancer
Interventions: DRUG: XL184|DRUG: Placebo|DRUG: XL184|DRUG: XL184
Sponsor: Exelixis